In re Isolagen, Inc. Securities Litigation

Securities fraud class action filed on behalf of all persons and entities who purchased or acquired publicly traded securities of Isolagen, Inc. ("Isolagen" or the "Company") between March 3, 2004 and August 9, 2005 (the "Class Period").

On April 4, 2006, the Honorable Ronald L. Buckwalter S.J. appointed BLB&G clients Context Capital Management, LCC and Michael McNulty as Co-Lead Plaintiffs and BLB&G as Co-Lead Counsel for the Class.

On July 14, 2006, BLB&G, Context Capital Management, LCC and Michael McNulty filed a Consolidated Class Action Complaint on behalf of the Class.

The Complaint charges that Isolagen and certain of its officers and directors disseminated materially false and misleading information to investors regarding, among other things, the Company's chances of obtaining FDA approval for its use of the "Isolagen Process" to treat facial wrinkles. During the Class Period, Isolagen claimed to investors that its "Isolagen Process" could effectively, and ultimately profitably, use a patient's own cells to reduce the normal effects of aging on skin, such as wrinkles and creases.

September 26, 2007 - Judge Buckwalter Clears Way for Isolagen Class Action to Proceed; Denies All of Defendants' Efforts to Dismiss Plaintiffs' Claims

On September 26, 2007, the Honorable Ronald L. Buckwalter issued an opinion denying all motions to dismiss filed by Defendants. Accordingly, the Isolagen Class Action will now proceed against all defendants named in Plaintiffs' First Corrected Class Action Complaint, including Isolagen, Inc., Isolagen's executives, CIBC World Markets Corp., Canaccord Adams, Inc., UBS Securities LLC and Citigroup Global Markets Inc.

Background

On August 1, 2005, Isolagen shocked the market by disclosing that the preliminary results from its clinical trial had not met all of the primary end points and that one of the two separate dermal studies had failed to demonstrate statistical significance. Accordingly, FDA approval would not be achieved as promised. As a result of this announcement, the Company's stock price plummeted more than 45 percent, from $5.59 per share to $2.89 per share, on very high volume.

In addition, Isolagen claimed during the Class Period that it was developing an "Automated Cellular Expansion" (ACE) system that would permit the Company to grow cells in large numbers and distribute them to tens of thousands of patients globally. During the Class Period, Isolagen assured the public that it was in the final stages of developing the ACE system, which was vital to its commercial success. However, during a conference call on August 9, 2005, Isolagen revealed that the ACE system was, in fact, far from implementation. In response to this startling disclosure, Isolagen's stock declined to $2.50 on August 10 from a previous close of $2.66 on high volume.

Defendants' scheme to mislead the investing public concerning Isolagen's chances of obtaining FDA approval of the Isolagen Process and to mass produce its sole product inflated the price of the Company's securities and allowed Isolagen to sell millions of dollars of new securities to investors - even while the Company's executives were dumping their own Isolagen stock at artificially inflated prices.

Other Cases of Interest

Citigroup, Inc.Southern District of New York
John C. Browne, David Wales, John Rizio-Hamilton, Benjamin Galdston, Jeremy P. Robinson